GLP-1 Drugs Reduce Heart Attacks and Death in Non-Diabetic Obese Adults: Meta-Analysis of 28,168 Participants

GLP-1/GIP RAs vs placebo in non-diabetic overweight/obese adults: MACE reduced (OR 0.79, 95% CI 0.71-0.89), all-cause mortality reduced (OR 0.80, 95% CI 0.70-0.92), MI reduced (OR 0.72, 95% CI 0.61-0.86), nonfatal MI reduced (OR 0.72, 95% CI 0.61-0.85). Cardiovascular mortality trend (OR 0.84, 95% CI 0.71-1.01, p=0.06). No significant stroke reduction. No heterogeneity across studies (I²=0 for all outcomes).

Systematic review and meta-analysis of 16 RCTs (13 GLP-1 RA trials, 3 tirzepatide trials) per PRISMA guidelines. Registered on PROSPERO (CRD42024515966). 28,168 overweight/obese adults without diabetes. Outcomes: MACE, all-cause and cardiovascular mortality, MI, and stroke. Pooled odds ratios with 95% CIs.

Until now, the cardiovascular benefits of GLP-1 RAs were primarily demonstrated in diabetic populations. This meta-analysis proves that these drugs also protect hearts in non-diabetic obese people — a much larger population. This shifts the value proposition of GLP-1 drugs from 'diabetes medication with weight loss benefits' to 'cardiovascular protective therapy for anyone with obesity.'

This meta-analysis extends the cardiovascular protective umbrella of GLP-1 drugs beyond diabetes. With obesity affecting over 650 million adults worldwide, the potential public health impact is enormous. These findings are likely to reshape obesity treatment guidelines and insurance coverage policies, positioning GLP-1 RAs as cardiovascular-protective medications for the general obese population.

Individual trial follow-up periods may be insufficient to fully capture cardiovascular events. Most participants likely had at least some cardiovascular risk factors beyond obesity. Stroke data are limited. The trend for CV mortality (p=0.06) needs confirmation with longer follow-up. Cost-effectiveness in non-diabetic populations hasn't been established.